Pentamethylquercetin Attenuates Cardiac Remodeling via Activation of the Sestrins/Keap1/Nrf2 Pathway in MSG-Induced Obese Mice

Figure 1

PMQ ameliorated obesity and metabolic disorders in MSG-IO mice at the 24th week. PMQ treatment resulted in significant reductions in (a) body weight, (b) body weight gain, (c) waist circumference, and (d) LEE index. Hyperglycemia (e), hyperinsulinaemia (f), and HOMA-IR (g) were significantly improved after PMQ treatment compared with the corresponding MSG-IO mice. (h) Left: effect of PMQ on the glucose tolerance disorder, as measured by the oral glucose tolerance test (OGTT). Right: area under the curve (AUC). Data are expressed as mean ± SEM, n = 12. vs. control group; , , vs. MSG group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)